gastroesophageal junction adenocarcinoma
MSD and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers
This is the first and only perioperative immunotherapy approved to treat early gastric cancers
AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer
Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually
Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer
The combination treatment showed a 35% reduction in the risk of disease progression
AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers
In 2022, nearly one million new patients were diagnosed with gastric cancer
Global Healthy Living Foundation and Medscape Education Join Forces to Bridge the Gap Between Patients and Providers with Immunology Education
UPPER NYACK, N.Y.--(BUSINESS WIRE)--The Global Healthy Living Foundation (GHLF) today announced a new partnership with Medscape Education to advance patient-centered innovation within the Immunology Learning Nexus (Nexus), Medscape’s flagship multi-year...
David Weinreich appointed as Merck’s Global Head of R&D and CMO, Healthcare
Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site
MSD receives NICE recommendation for Keytruda in advanced endometrial cancer
More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK
AstraZeneca’s Imfinzi granted FDA priority review to treat early-stage gastric cancer
Gastric cancer is the fifth leading cause of cancer-related deaths globally
Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study
Almost one million new cases of gastric cancer are diagnosed globally every year
Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer
More than 72,680 new cases of the disease are expected to be diagnosed in the US this year
Merck shares promising phase 3 results for Keytruda in ovarian cancer
Approximately 20,890 cases of the disease are expected to be diagnosed in the US this year